Literature DB >> 20737576

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.

Hagop M Kantarjian1, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Elias Jabbour, Guillermo Garcia-Manero, Sherry Pierce, Jianquin Shan, Jorge Cortes, Susan O'Brien.   

Abstract

BACKGROUND: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics.
METHODS: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted.
RESULTS: Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72).
CONCLUSIONS: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20737576      PMCID: PMC4332768          DOI: 10.1002/cncr.25354

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

Review 2.  Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

Authors:  A Thiebaut; J P Vernant; L Degos; F R Huguet; J Reiffers; C Sebban; E Lepage; X Thomas; D Fière
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

3.  Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Authors:  D A Thomas; H Kantarjian; T L Smith; C Koller; J Cortes; S O'Brien; F J Giles; J Gajewski; S Pierce; M J Keating
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

4.  The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia.

Authors:  S L George; J J Ochs; A M Mauer; J V Simone
Journal:  J Clin Oncol       Date:  1985-06       Impact factor: 44.544

5.  Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

6.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Authors:  Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Jose Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W Deininger; Charles A Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

Review 7.  Clofarabine for the treatment of acute lymphoblastic leukemia.

Authors:  Sima Jeha; Hagop Kantarjian
Journal:  Expert Rev Anticancer Ther       Date:  2007-02       Impact factor: 4.512

8.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Authors:  J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

9.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors:  E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

10.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Authors:  Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113

View more
  48 in total

1.  Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.

Authors:  Anthony S Stein; Richard A Larson; Andre C Schuh; William Stevenson; Ewa Lech-Maranda; Qui Tran; Zachary Zimmerman; William Kormany; Max S Topp
Journal:  Blood Adv       Date:  2018-07-10

2.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

Review 3.  Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.

Authors:  Michael S Mathisen; Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Elias Jabbour
Journal:  Leuk Lymphoma       Date:  2013-06-21

4.  Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Authors:  Gerhard Zugmaier; Nicola Gökbuget; Matthias Klinger; Andreas Viardot; Matthias Stelljes; Svenja Neumann; Heinz-A Horst; Reinhard Marks; Christoph Faul; Helmut Diedrich; Albrecht Reichle; Monika Brüggemann; Chris Holland; Margit Schmidt; Hermann Einsele; Ralf C Bargou; Max S Topp
Journal:  Blood       Date:  2015-10-19       Impact factor: 22.113

5.  Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Nicholas J Short; Jeffrey L Jorgensen; Musa Yilmaz; Farhad Ravandi; Sa A Wang; Deborah A Thomas; Joseph Khoury; Richard E Champlin; Issa Khouri; Partow Kebriaei; Susan M O'Brien; Guillermo Garcia-Manero; Jorge E Cortes; Koji Sasaki; Courtney D Dinardo; Tapan M Kadia; Nitin Jain; Marina Konopleva; Rebecca Garris; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-09-07       Impact factor: 6.860

6.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hervè Dombret; Jose-Maria Ribera; Adele K Fielding; Anjali Advani; Renato Bassan; Victoria Chia; Michael Doubek; Sebastian Giebel; Dieter Hoelzer; Norbert Ifrah; Aaron Katz; Michael Kelsh; Giovanni Martinelli; Mireia Morgades; Susan O'Brien; Jacob M Rowe; Julia Stieglmaier; Martha Wadleigh; Hagop Kantarjian
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

7.  Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.

Authors:  Elias Jabbour; Susan O'Brien; Xuelin Huang; Deborah Thomas; Michael Rytting; Koji Sasaki; Jorge Cortes; Guillermo Garcia-Manero; Tapan Kadia; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2015-01-16       Impact factor: 10.047

Review 8.  Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Authors:  Katharine A Hodby; David I Marks
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

Review 9.  Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.

Authors:  Jacob S Appelbaum; Filippo Milano
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  The myth of the second remission of acute leukemia in the adult.

Authors:  Stephen J Forman; Jacob M Rowe
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.